Clinical trial
A Phase 2 Open-Label Trial to Evaluate the Efficacy and Safety of the Hepcidin Mimetic Rusfertide (TAK-121) in Chinese Patients With Polycythemia Vera
NCT07765602 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open-Label Trial to Evaluate the Efficacy and Safety of the Hepcidin Mimetic Rusfertide (TAK-121) in Chinese Patients With Polycythemia Vera
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 1, 2027
- Completion date
- August 1, 2028
- Enrollment
- 24 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.